Free Trial

Akoya Biosciences Q4 2024 Earnings Report

Akoya Biosciences logo
$1.38 -0.05 (-3.15%)
As of 12:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Akoya Biosciences EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.15
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Akoya Biosciences Revenue Results

Actual Revenue
$21.34 million
Expected Revenue
$21.34 million
Beat/Miss
Beat by +$3.00 thousand
YoY Revenue Growth
N/A

Akoya Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Akoya Biosciences Earnings Headlines

Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Drops By 30.8%
[OPEN NOW] New rules to trade options with.
Here’s an update that could make your entire year. But first, a question. Could you get better wins if you applied a new set of rules to your trade? For example, when you meet your criteria to take a trade, could you improve your results by taking the same trade differently? From the audit I just did, it turns out the answer is a resounding YES! I applied a new set of rules to 100 live published trades from 2024. These 100 trades already got a whopping 69% win rate – taking a $10k model account risking 10% per trade to $63,304. But what happened when we applied these new rules? We got an 85.1% win rate and sent the same $10k account risking 10% per trade to over $200k!
See More Akoya Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akoya Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akoya Biosciences and other key companies, straight to your email.

About Akoya Biosciences

Akoya Biosciences (NASDAQ:AKYA), a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

View Akoya Biosciences Profile

More Earnings Resources from MarketBeat